Categories: News

Repligen to Report Third Quarter 2021 Financial Results

Webcast and Conference Call to Be Held Thursday, October 28, 2021 at 8:30 a.m. EDT

WALTHAM, Mass., Oct. 14, 2021 (GLOBE NEWSWIRE) — Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its third quarter 2021 financial results on Thursday, October 28, 2021. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. EDT to discuss business updates and financial results for the three- and nine- month reporting periods ended September 30, 2021.

The conference call will be accessible by dialing toll-free (844) 274-3999 for domestic callers and (412) 317-5607 for international callers. No passcode is required for the live call. In addition, a webcast will be accessible via the Investor Relations section of the Company’s website. Both the conference call and webcast will be archived for a period of time following the live event. The replay dial-in numbers are (877) 344-7529 for callers in the U.S., (855) 669-9658 for callers in Canada and (412) 317-0088 for international callers. Replay listeners must provide the passcode 10161245.

About Repligen Corporation
Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that increase efficiencies in the process of manufacturing biological drugs. We are inspiring advances in bioprocessing for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our corporate headquarters are located in Waltham, Massachusetts, with additional administrative and manufacturing operations worldwide. The majority of our manufacturing sites are located within the U.S. (California, Massachusetts, New Jersey and New York), and outside of the U.S. we have sites in Estonia, France, Germany, Ireland, the Netherlands and Sweden. For more information about the company, including Repligen news releases, see our website at www.repligen.com. Follow us on LinkedIn and Twitter.

This press release may contain forward-looking statements within the meaning of the federal securities laws. Investors are cautioned that statements in this press release which are not strictly historical statements including, without limitation, statements identified by words like “believe,” “expect,” “may,” “will,” “should,” “seek,” or “could” and similar expressions, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including risks discussed from time to time in our filings with the Securities and Exchange Commission. We expressly disclaim any responsibility to update any forward-looking statements, except as required by law.

Repligen Contact:
Sondra S. Newman
Global Head of Investor Relations
(781) 419-1881
investors@repligen.com

Staff

Recent Posts

Functional Brands Inc. to Participate at the Sidoti Year End Virtual Investor Conference

Lake Oswego, Oregon--(Newsfile Corp. - December 8, 2025) - Functional Brands Inc. (NASDAQ: MEHA), a…

47 minutes ago

Cheelcare Has a Record Month of Sales and Celebrates Milestone of 2,000 Companions Sold

Markham, Ontario--(Newsfile Corp. - December 8, 2025) - Cheelcare (TSXV: CHER), a Canadian innovator in…

2 hours ago

SJTU International Gen Z Students Explore Shanghai’s Innovation Ecosystem

SHANGHAI, Dec. 8, 2025 /PRNewswire/ -- Shanghai Jiao Tong University's Antai Global Summer Program (AGSP)…

3 hours ago

Evotec Closes Sale of Just – Evotec Biologics’ Toulouse Site to Sandoz

All closing requirements satisfied following announcement of a non-binding term-sheet agreement in July and signing…

6 hours ago

RESPIREE SECURES SINGAPORE HSA APPROVAL FOR ITS AI-ENABLED 1BIO™AI SOFTWARE TO SUPPORT ACUTE DETERIORATION DETECTION

SINGAPORE, Dec. 7, 2025 /PRNewswire/ -- AI/ML health-tech startup Respiree has received approval from the Health…

9 hours ago

AI-for-Science Startup ChemLex Raises USD 45M, Launching Self-Driving Lab for Drug Discovery in Singapore

SINGAPORE, Dec. 7, 2025 /PRNewswire/ -- ChemLex, a next-generation AI-for-science company, today announced the establishment…

9 hours ago